Radioangiocardiogram monitoring in patients receiving bisantrene.
Due to the tricyclic structural similarity between the anthracyclines and a new anthracene bishydrazone derivative, bisantrene, changes in myocardial function as detected by radionuclide angiography were sought in early phase I-II trials of the drug. Overall, there appear to be no changes in ejection fraction when determined 24 hours postinfusion, or when determined after low cumulative doses of bisantrene.
D000873:Anthracenes / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D004341:Drug Evaluation; D006321:Heart / Q000000981:diagnostic imaging* / Q000187:drug effects; D006801:Humans; D011877:Radionuclide Imaging; D013318:Stroke Volume / Q000187:drug effects
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene